Related references
Note: Only part of the references are listed.Long-Term Efficacy of Rosiglitazone in Nonalcoholic Steatohepatitis: Results of the Fatty Liver Improvement by Rosiglitazone Therapy (FLIRT 2) Extension Trial
Vlad Ratziu et al.
HEPATOLOGY (2010)
Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-γ ligand rosiglitazone
BA Neuschwander-Tetri et al.
HEPATOLOGY (2003)
Role of AMP-activated protein kinase in mechanism of metformin action
GC Zhou et al.
JOURNAL OF CLINICAL INVESTIGATION (2001)
Prevalence of and risk factors for hepatic steatosis in northern Italy
S Bellentani et al.
ANNALS OF INTERNAL MEDICINE (2000)
Share Paper
